Safety And Efficacy Of Anti-IL-5 Monoclonal Antibody For The Treatment Of Chronic Rhinosinusitis?Meta Analysis

Objective:There are several methods for the treatment of CRS,but many patients still have difficulty controlling the disease.Recently,literature has emerged as a potential therapy for anti-IL-5 monoclonal antibodies as CRS.Anti-IL-5 monoclonal antibodies include:Mepolizumab,Reslizumab,and Benralizumab.However,their efficacy and safety are not known.In this article,the meta-analysis was used to evaluate the quality and statistical analysis of published randomized controlled trials of anti-IL-5 monoclonal antibody in the treatment of CRS at home and abroad,,and to investigate the efficacy and safety of anti-IL-5 monoclonal antibodies against CRS patients.Clinical treatment CRS provides evidence based evidence.Methods:Computer search of Pubmed,Medline,Ovid Medline,Cochrane,Embase,China Biomedical Literature Database(CBM),CNKI,VIP,Wanfang,etc.,and manual retrieval of conference proceedings,publications,and conferences Abstract,clinical trial website,etc.Retrieval period Since the establishment of the database to December 2017,randomized controlled trials were conducted to screen anti-IL-5 monoclonal antibodies for the treatment of CRS.Meta-analysis was performed on literature that met the inclusion criteria,and meta-analysis was performed using Rev Man5.3 software.Results:After the literature screening,the final three documents meet the requirements,all ofwhich are randomized controlled trials(RCT).All of them are English literature,and 159 patients were included in the study,90 in the experimental group and 69 in the control group.The experimental group treated with anti-IL-5 monoclonal antibody was compared with the placebo-treated control group.The results included TPS,Lund-Mackay CT Score and others.Outcome scores.In the three studies,anti-IL-5treatment showed a standard mean difference in TPS improvement of-1.11(95% CI,-1.65 to-0.57).In one study,CT scores improved significantly.In the three trials,other outcome measures,including the measurement of clinical symptoms(smell,runny nose,general nasal congestion,etc.)and nasal inspiratory peak flow(nPIF),were insignificantly different and were not statistically significant.Anti-IL-5 therapy occurred in 1 case with serious drug-related complications reported,other adverse reactions were mild,safe and well tolerated.Based on quality assessments,the risk of RCT bias is moderate.Conclusion:? In the meta-analysis,anti-IL-5 treatment resulted in a decrease in the number of clinical polyps,a better CT score,and better efficacy compared with placebo.Anti-IL-5therapy may be a treatment for refractory CRS with or without nasal polyposis.benefit.? Anti-IL-5 monoclonal antibody in the treatment of CRS occurred in 1 case of serious adverse reactions,treatment safety,well tolerated,but not recommended as a first-line treatment.? Current evidence cannot fully determine the effectiveness of anti-IL-5monoclonal antibodies in the treatment of CRS,and additional high-level evidence is needed to assess clinical efficacy.